This is an external link. Click “OK” to continue.
Having first met him in university, Antibe’s founder, John Wallace, reconnected with Dan nearly 30 years later, seeking to tap his talent for leading senior teams in building best-in-class ventures.
JD Queen’s University, Canada
Law Society of Upper Canada
New York State Bar, USA
Dan’s leadership experience began with eight years as a military pilot, principally as an air rescue captain.
“We think we’ve solved one of the significant, long-standing medical problems of our time.”
John is widely recognized as an expert in gastrointestinal inflammation and in the development of innovative anti-inflammatory medicines. In the mid-1990s, he co-founded NicOx and chaired its Scientific Advisory Board. (NicOx was the first company to achieve regulatory approval for drugs using gasotransmitters.)
PhD Medical Science University of Toronto, Canada
British Pharmacological Society
Royal Society of Canada
John received the Premier’s Summit Award in Innovation in 2009, financially the largest prize awarded to an individual scientist in Canada. He is also the recipient of the 2011 William Harvey Medal from the William Harvey Institute in London, UK. John was awarded the Heymans Foundation Medal in 2013—one of only twelve scientists so honored since the foundation was established nearly 50 years ago.
“Gastrointestinal damage from NSAIDs has been a clinically significant problem since first observed with aspirin, which was introduced more than 100 years ago.”
Following his medical training, Dr. Joseph (“Joe”) Stauffer practiced frontline medicine for a decade, including eight years as a US Navy general practice physician. He then joined the US Food and Drug Administration (FDA) as a Medical Review Officer for anti-inflammatory and analgesic drugs, subsequently being recruited by Abbott Laboratories as Global Medical Director.
DO Philadelphia College of Osteopathic Medicine, US
ANESTHESIOLOGY RESIDENCY The Johns Hopkins University School of Medicine, University Hospital, US
MBA New York University, US; London School of Economics, UK; Hautes Etudes Commerciales, France
College on Problems of Drug Dependence
Joe is a founding member of the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials (“IMMPACT”), which became an official public-private partnership between pharmaceutical companies, the FDA, the National Institutes of Health, academia and patient advocacy organizations across the US.
“Antibe represents one of the few truly novel platforms in the field, and I look forward to playing a role in navigating its drug pipeline through the later stages of clinical development.”
As a scientist and drug development executive, David has extensive experience in bringing drugs from early investigation to regulatory approval. Acting as a product development consultant for several major pharmaceutical firms, he has advanced treatments for bacterial infections and disorders of the central nervous and gastrointestinal systems.
|PhD Clinical Pathology and Biochemistry University of Toronto, Canada|
“I value the opportunity to develop a platform that validates a novel NSAID—a drug that can improve the quality of life for so many people suffering from daily pain.”
Alain is a seasoned CFO and consultant to private and public companies. He is a founding partner of Revelstoke Partners, a boutique consulting firm focused on assisting mid-market companies in challenging circumstances, such as extreme growth or a fundamental change in business model.
MBA International Institute for Management Development (IMD), Switzerland
BComm (Honours) Queen’s University, Canada
“I see Antibe’s mission in the context of my own family—my grandfather had major stomach surgery because of NSAIDs.”
Scott brings a unique perspective to funding and growing healthcare companies from his broad capital markets experience, where he was able to leverage his academic background in life sciences and computer engineering. His interest in biotechnology was sparked by the Human Genome Project and his studies in biomedical computing.
Prior to Antibe, he was an investment banking professional with Bloom Burton & Co., a leading healthcare-focused investment dealer and advisory firm. Scott was also an Equity Research Analyst at Cantor Fitzgerald Canada where his coverage included Specialty Pharma.
MEng Computer Engineering University of Toronto, Canada
CFA® Charterholder (Chartered Financial Analyst)
“What struck me about Antibe from the beginning was that they were targeting a massive medical problem with a disruptive, best-in-class technology.”
In his most recent role, Rami headed the outreach and partnership efforts at Spectrum Therapeutics, a Canopy Growth Corporation subsidiary that focuses on cannabinoid therapeutics. He had previously led the company’s research and development effort, involving several clinical development programs and discovery initiatives addressing nervous system disorders (including pain) and cancer supportive care.
PhD Experimental Medicine McGill University, Canada
Rami and his teams have identified and evaluated hundreds of products and product candidates in clinical and preclinical development.
“Pain is a ‘screaming’ and multi-faceted medical need, and it’s central to successful disease management. I believe that Antibe’s research program is a path to better medicines for pain.”
With more than 25 years of experience in the design and management of new drug development programs, Craig is an expert in gaining regulatory approval in key markets worldwide. His work has involved corporate representation at regulatory agencies, including the FDA, Health Canada, MHRA (UK), and the EMA (EU).
|PhD Microbiology University of Glasgow, UK|
Postdoctoral studies as Fulbright Scholar at Harvard University, USA
“In a landscape dominated by specialized drugs for rare diseases, I’m excited to work on a pipeline that targets safer analgesia for billions of people.”
With more than 20 years of capital markets experience in life sciences, Christina’s background includes positions in investment banking, equity sales and investor relations.
BBA Wilfred Laurier University, Canada
“At Antibe, what drives me is the dramatic difference our drugs could make to the lives of millions of patients.”
|A business development executive and scientist, Ella was most recently Vice President, Business Development for Advanced Proteome Therapeutics, a publicly traded biopharma company.
Earlier, she was Global Brand Manager for Nordion, where she was responsible for product marketing in the US and Asia. As Director of Business Development for IMV (NASDAQ: IMV), she spearheaded its critical licensing deal with Merck.
|MSc Medical Genetics University of Toronto, Canada
MBA Dalhousie University, Canada
Ella is founding CEO and director of TO Health!, a unique platform to convene the Toronto Region Health Cluster and develop the biotech sector — launched by the Toronto Region Board of Trade and incubated by MaRS Discovery District.
“When it comes to building strong partnerships, there’s no substitute for relationships, reputation and good data!”
As a communicator and strategist, Philip has been contributing to the Antibe project since 2006. Over his career, he has been a senior advisor in pharma, dental products, medical devices, fintech, and a range of internet and IT technologies.
He is co-founder of Simon/Ross + Associates, which became the world’s leading Apple-focused computer training company, and a former lecturer in the Department of Computer Science at the University of Toronto.
MBA Harvard Business School, USA
BCom McGill University, Canada
Philip was co-founder and marketing head of Workfire Networks, a breakthrough internet infrastructure company acquired for $100 million by Packeteer.
“The year I began working with Antibe, my mom had emergency surgery because of NSAIDs … so this is personal!”